Interleukin-2: Biology, Design and Application

Trends in Immunology

Volumn 36, Issue 12, 2015, Pages 763-777

  Arenas Ramirez, Natalia ^a   Woytschak, Janine ^a   Boyman, Onur ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2; STAT5 PROTEIN; UNCLASSIFIED DRUG;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG FORMULATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; LYMPHOID CELL; MAST CELL; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; IMMUNOLOGY; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; INTERLEUKIN-2; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, REGULATORY;

EID: 84949727634     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.10.003     Document Type: Review

References (87)

1. Morgan D.A., et al. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976, 193:1007-1008.
2. Robb R.J., Smith K.A. Heterogeneity of human T-cell growth factor(s) due to variable glycosylation. Mol. Immunol. 1981, 18:1087-1094.
3. Taniguchi T., et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983, 302:305-310.
4. Smith K.A. Interleukin-2: inception, impact, and implications. Science 1988, 240:1169-1176.
5. Rosenberg S.A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 2014, 192:5451-5458.
6. Boyman O., Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 2012, 12:180-190.
7. Klatzmann D., Abbas A.K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 2015, 15:283-294.
8. Wang X., et al. Structure of the quaternary complex of interleukin-2 with its α, β, and γc receptors. Science 2005, 310:1159-1163.
9. Boyman O., et al. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006, 311:1924-1927.
10. Rosalia R.A., et al. Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. Curr. Opin. Chem. Biol. 2014, 23:39-46.
11. Saadoun D., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 2011, 365:2067-2077.
12. Koreth J., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 2011, 365:2055-2066.
13. Spangler J.B., et al. Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms. Immunity 2015, 42:815-825.
14. Mitra S., et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity 2015, 42:826-838.
15. Yu A., et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes 2015, 64:2172-2183.
16. von Spee-Mayer C., et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2015, Published online August 31, 2015. 10.1136/annrheumdis-2015-207776.
17. Malek T.R., Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010, 33:153-165.
18. Liao W., et al. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38:13-25.
19. Taniguchi T., Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993, 73:5-8.
20. Letourneau S., et al. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J. Allergy Clin. Immunol. 2009, 123:758-762.
21. Hemar A., et al. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor α, β, and γ chains. J. Cell Biol. 1995, 129:55-64.
22. Yu A., et al. Efficient internalization of IL-2 depends on the distal portion of the cytoplasmic tail of the IL-2R common γ-chain and a lymphoid cell environment. J. Immunol. 2000, 165:2556-2562.
23. Zelante T., et al. Interleukin-2 production by dendritic cells and its immuno-regulatory functions. Front. Immunol. 2012, 3:161.
24. + T cells. Science 2010, 327:1098-1102.
25. Amado I.F., et al. IL-2 coordinates IL-2-producing and regulatory T cell interplay. J. Exp. Med. 2013, 210:2707-2720.
26. Lenardo M.J. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 1991, 353:858-861.
27. Van Parijs L., Abbas A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998, 280:243-248.
28. Wang H.M., Smith K.A. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J. Exp. Med. 1987, 166:1055-1069.
29. Sakaguchi S., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
30. Roediger B., et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat. Immunol. 2013, 14:564-573.
31. Krieg C., et al. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11906-11911.
32. Mingari M.C., et al. Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature 1984, 312:641-643.
33. Zubler R.H., et al. Activated B cells express receptors for, and proliferate in response to, pure interleukin 2. J. Exp. Med. 1984, 160:1170-1183.
34. Wuest S.C., et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 2011, 17:604-609.
35. Yu A., et al. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009, 30:204-217.
36. Malek T.R., et al. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice, Implications for the nonredundant function of IL-2. Immunity 2002, 17:167-178.
37. Sharma, R. et al. (2007) A regulatory T cell-dependent novel function of CD25 (IL-2Rα) controlling memory CD8+ T cell homeostasis. J. Immunol. 178, 1251-1255.
38. + memory T cells. Nature 2006, 441:890-893.
39. Boyman O., et al. The role of interleukin-2 in memory CD8 cell differentiation. Adv. Exp. Med. Biol. 2010, 684:28-41.
40. McKinstry K.K., et al. Effector CD4 T-cell transition to memory requires late cognate interactions that induce autocrine IL-2. Nat. Commun. 2014, 5:5377.
41. Long S.A., et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012, 61:2340-2348.
42. Hartemann A., et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013, 1:295-305.
43. Matsuoka K., et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci. Transl. Med. 2013, 5:179ra143.
44. Cunningham-Rundles C., et al. Restoration of immunoglobulin secretion in vitro in common variable immunodeficiency by in vivo treatment with polyethylene glycol-conjugated human recombinant interleukin-2. Clin. Immunol. Immunopathol. 1992, 64:46-56.
45. Kovacs J.A., et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 1996, 335:1350-1356.
46. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 2009, 361:1548-1559. INSIGHT-ESPRIT Study Group.
47. Letourneau S., et al. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2171-2176.
48. Jin G.H., et al. Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation. Int. Immunol. 2008, 20:783-789.
49. Verdeil G., et al. Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16683-16688.
50. + T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. J. Immunol. 2009, 183:4904-4912.
51. Levin A.M., et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 2012, 484:529-533.
52. Redmond W.L., et al. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression. PLoS ONE 2012, 7:e34467.
53. Cho H.I., et al. A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res. 2012, 72:1986-1995.
54. Molloy M.J., et al. Cutting edge: IL-2 immune complexes as a therapy for persistent virus infection. J. Immunol. 2009, 182:4512-4515.
55. Hamilton S.E., et al. IL-2 complex treatment can protect naive mice from bacterial and viral infection. J. Immunol. 2010, 185:6584-6590.
56. Webster K.E., et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 2009, 206:751-760.
57. Van Gool F., et al. Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood 2014, 124:3572-3576.
58. Vokaer B., et al. IL-17A and IL-2-expanded regulatory T cells cooperate to inhibit Th1-mediated rejection of MHC II disparate skin grafts. PLoS ONE 2013, 8:e76040.
59. Tang Q., et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28:687-697.
60. Liu R., et al. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur. J. Immunol. 2010, 40:1577-1589.
61. Lee S.Y., et al. Interleukin-2/anti-interleukin-2 monoclonal antibody immune complex suppresses collagen-induced arthritis in mice by fortifying interleukin-2/STAT5 signalling pathways. Immunology 2012, 137:305-316.
62. Wilson M.S., et al. Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells. J. Immunol. 2008, 181:6942-6954.
63. Feuerer M., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 2009, 15:930-939.
64. + regulatory T cells and attenuates development and progression of atherosclerosis. Circulation 2012, 126:1256-1266.
65. Villalta S.A., et al. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci. Transl. Med. 2014, 6:258ra142.
66. Donohue J.H., Rosenberg S.A. The fate of interleukin-2 after in vivo administration. J. Immunol. 1983, 130:2203-2208.
67. Lotze M.T., et al. In vivo administration of purified human interleukin 2, II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 1985, 135:2865-2875.
68. Konrad M.W., et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res. 1990, 50:2009-2017.
69. Boyman O., et al. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin. Biol. Ther. 2006, 6:1323-1331.
70. Phelan J.D., et al. Cutting edge: mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies. J. Immunol. 2008, 180:44-48.
71. Polhill T., et al. IL-2/IL-2Ab complexes induce regulatory T cell expansion and protect against proteinuric CKD. J. Am. Soc. Nephrol. 2012, 23:1303-1308.
72. Rickert M., et al. The structure of interleukin-2 complexed with its alpha receptor. Science 2005, 308:1477-1480.
73. Reem G.H., et al. Induction and upregulation by interleukin 2 of high-affinity interleukin 2 receptors on thymocytes and T cells. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:8663-8666.
74. Shanafelt A.B., et al. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat. Biotechnol. 2000, 18:1197-1202.
75. Laurent J., et al. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J. Transl. Med. 2013, 11:5.
76. Margolin K., et al. Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin. Cancer Res. 2007, 13:3312-3319.
77. Hu P., et al. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood 2003, 101:4853-4861.
78. Carmenate T., et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J. Immunol. 2013, 190:6230-6238.
79. Klein C., et al. Tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for the immunotherapy of cancer [abstract]. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research. Cancer Res. 2013, 73:486.
80. Ardolino M., et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J. Clin. Invest. 2014, 124:4781-4794.
81. Tomala J., et al. Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionally. ACS Chem. Biol. 2013, 8:871-876.
82. Arkin M.R., et al. Binding of small molecules to an adaptive protein-protein interface. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1603-1608.
83. Hess C., et al. Emerging classes of armed antibody therapeutics against cancer. MedChemComm 2014, 5:408-431.
84. Boyman O., et al. Adverse reactions to biologic agents and their medical management. Nat. Rev. Rheumatol. 2014, 10:612-627.
85. Allegretta M., et al. The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2). J. Clin. Immunol. 1986, 6:481-490.
86. Scharenberg J.G., et al. The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2. Eur. J. Cancer 1994, 30A:1804-1809.
87. Prummer O. Treatment-induced antibodies to interleukin-2. Biotherapy 1997, 10:15-24.